• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Zagazig University Medical Journal
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 29 (2023)
Volume Volume 28 (2022)
Issue Issue 6.1
supplement 1
Issue Issue 6
Issue Issue 6.2
supplement 2
Issue Issue 5
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 27 (2021)
Volume Volume 26 (2020)
Volume Volume 25 (2019)
Volume Volume 24 (2018)
Volume Volume 23 (2017)
Volume Volume 22 (2016)
Volume Volume 21 (2015)
Volume Volume 20 (2014)
Volume Volume 19 (2013)
Rezk, N., Elsayed Sileem, A., Gad, D., Khalil, A. (2022). miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin. Zagazig University Medical Journal, 28(3), 573-582. doi: 10.21608/zumj.2021.92746.2329
Noha Rezk; Ashraf Elsayed Sileem; Doaa Gad; amr osam Khalil. "miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin". Zagazig University Medical Journal, 28, 3, 2022, 573-582. doi: 10.21608/zumj.2021.92746.2329
Rezk, N., Elsayed Sileem, A., Gad, D., Khalil, A. (2022). 'miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin', Zagazig University Medical Journal, 28(3), pp. 573-582. doi: 10.21608/zumj.2021.92746.2329
Rezk, N., Elsayed Sileem, A., Gad, D., Khalil, A. miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin. Zagazig University Medical Journal, 2022; 28(3): 573-582. doi: 10.21608/zumj.2021.92746.2329

miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin

Article 24, Volume 28, Issue 3, May 2022, Page 573-582  XML PDF (351.68 K)
Document Type: Original Article
DOI: 10.21608/zumj.2021.92746.2329
Authors
Noha Rezk email 1; Ashraf Elsayed Sileem2; Doaa Gad3; amr osam Khalil4
1Medical biochemistry .zagazig university
2chest department, faculty of medicine, zagazig university
3Chest department, faculty of medicine, Zagazig University
4Lecturer of Radio-diagnosis, Faculty of Medicine – Zagazig University
Abstract
The role of Ivermectin in improving the outcome of coronavirus disease of 2019 (COVID-19) symptoms was reported in several studies, while its effect on the pro-inflammatory cytokines triggering the cytokine storm is still not investigated.
This study aimed to investigate the role of Ivermectin on the proinflammatory cytokines in Covid-19 patients and correlated the results with the expression of miR-2909, miR-223-3p. Three hundred and twenty hospitalized patients with confirmed moderate-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were selected. The patients were divided into 2 groups: Group I treated with the Egyptian protocol of COVID-19 including (Ivermectin plus hydroxychloroquine). Group II was treated with the Egyptian protocol, including hydroxychloroquine and no Ivermectin. IL-6, IL-1b, procalcitonin, and gene expression of miR-2909, miR-223-3p, and Toll-like receptor 4 were done by real-time Polymerase Chain Reaction (PCR).
Patients treated with COVID-19 protocol including Ivermectin showed a significant decrease of cytokines levels (IL-6, IL-1, and procalcitonin), when compared with the other group, the cytokines levels improvement were positively correlated with miR-2029 expression and negatively correlated with the expression of miR-223-3p. Moderate ill COVID-19 patients treated with Ivermectin showed a significant decline in mortality rate and duration of hospital stay.
Ivermectin is an effective drug in improving the outcome of SARS-CoV-2 patients with a significant decrease in mortality rate through decreasing cytokines expression via controlling miR-2029, miR-233-3p expressions.
Keywords
Interleukin-6; ivermectin; mrna
Main Subjects
Chest
Statistics
Article View: 1,385
PDF Download: 706
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.